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Background: Renal cell carcinoma (RCC) represents 2%–3% of all cancers of the Western countries. Currently, sunitinib, a receptor
tyrosine kinase inhibitor, particularly of PDGF and VEGF receptors, is the ﬁrst-line therapy for metastatic RCC (mRCC), with signiﬁcant
improvement in clinical outcome. However, there is a lack of predictive biomarkers of sunitinib response. Recently, others and our group
suggested that the receptor tyrosine kinase AXL may modify the response to sunitinib.
Objective: To study the expression of AXL in a series patients with of mRCC treated with sunitinib and to correlate it with patient's
clinic-pathological features and therapeutic response.
Material and methods: Sixty-four patients with mRCC (51 clear cell carcinomas (CCCs) and 13 non-CCCs) were evaluated for AXL
expression by immunohistochemistry in the primary tumor.
Results: AXL positivity was observed in 47% (30/64) of cases, namely in 43% (22/51) of CCCs and 61% (8/13) of non-CCC. Considering
only the clear cell subtype, the univariate analysis showed that AXL expression was statistically associated with a poor prognosis, with a
median overall survival of 13 months vs. 43 months in patients with negative AXL. In this subtype, along with the AXL positivity, other
prognostic factors were absence of nephrectomy, Karnofsky performance status, more than 1 site of metastasis and liver metastasis. Moreover,
AXL expression was associated with shorter progression to sunitinib. Overall, the multivariate survival analysis showed that absence of
nephrectomy (HR ¼ 4.85, P ¼ 0.001), more than 1 site of metastasis (HR ¼ 2.99, P ¼ 0.002), bone metastasis (HR ¼ 2.95, P ¼ 0.001),
together with AXL expression (HR ¼ 2.01, P ¼ 0.048) were independent poor prognostic factor in patients with mRCC.
Conclusion: AXL expression was associated with worse clinical outcome and may be an important prognostic biomarker in sunitinib-
treated patients with metastatic renal cell carcinoma. r 2018 Elsevier Inc. All rights reserved.Keywords: Renal cell carcinoma; AXL; Sunitinib; Cabozantinib; Prognostic biomarker1. Introduction
Kidney cancer is the seventh most common cancer in
men and tenth most common cancer in woman worldwide.urolonc.2017.09.003
ier Inc. All rights reserved.
. Tel.:þ55-173-321-6600.
hcb@gmail.com (R.M. Reis).[1]. Renal cell carcinoma (RCC) is responsible for 90% of
all kidney cancer, and approximately 80% of these are clear
cell tumors, with the other 20% being less common RCC
subtypes, like papillary and chromophobe tumors [2,3]. In
Brazil kidney cancer is the 15th cancer in incidence with
approximately 3,700 new cases per year responsible for
more than 2,000 deaths per year [4].
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autosomal dominant syndromes are described as responsible
for approximately 2%–3% of all RCCs, being the Von
Hippel Lindau (VHL) disease the most common form [5,6].
VHL disease is caused by a germline mutation in the VHL
gene that predisposes to clear cell RCC and other prolifer-
ative vascular tumors [7]. VHL gene plays an important
role, not only in hereditary but also in sporadic clear cell
cancer, since inactivation of VHL leads to elevated levels of
the transcription factor hypoxia-inducible factor 1α (HIF-
1α) and subsequent overexpression of vascular endothelial
growth factor (VEGF) and platelet-derived growth factor
(PDGF), which promote tumor angiogenesis. Bi-allelic VHL
gene alterations can occur through VHL gene mutations,
hypermethylation of VHL gene promoter and loss of
heterozygosity, which characterizes more than 80% of
sporadic cases [6].
In this scenario, the receptor tyrosine kinase inhibitors
(TKI), sunitinib, an anti-angiogenic agent, was tested in
phase III trial, leading to a longer progressing free survival
when compared to interferon (median: 11 vs. 5 mo,
respectively, hazard ratio (HR) ¼ 0.42; 95% CI: 0.32–
0.54; Po 0.001) and an improved overall survival (OS)
(median 26.4 vs. 21.8 mo, HR ¼ 0.82, 95% CI: 0.673–
1.001, P ¼ 0.051) [8,9]. Consequently, sunitinib was
approved and established as a standard of care in the
treatment of advanced RCC worldwide [5,10–12]. Despite
of this rational, TKIs rarely cause durable tumor regressions
and most patients will experience disease progression after
an initial period of response [13].
Remarkable efforts are being made to identify bio-
markers that may predict response to select and treat more
effectively patients with metastatic RCC (mRCC) [14].
AXL, a gene that encodes a receptor tyrosine kinase, is
involved with a wide variety of cancerous hallmarks such as
proliferation, survival, evasion from apoptosis, enhanced
angiogenesis, and invasiveness [15,16]. Recently, AXL
have been suggested as a biomarker of poor prognosis
and a potential target for different types of cancers [17,18],
including RCC [19,20]. Previously, our group suggested
that in glioblastoma cell lines, AXL can constitute a
predictive biomarker for sunitinib response [21,22]. In this
study, we evaluated the AXL presence in the primary tumor
through its expression in a cohort of 64 patients with mRCC
treated with sunitinib and its association with clinical-
pathological features and clinical outcome.2. Materials and methods
2.1. Patients and sampling
Sixty-four patients with mRCC treated with sunitinib
between 2008 and 2014 at Barretos Cancer Hospital were
included in this study. Patient inclusion criteria comprised a
diagnosis of mRCC of any pathologic subtype that hadreceived at least 1 course of sunitinib in any line and had
enough tissue samples for immunohistochemistry analysis.
We also divided the patients into 2 groups, the clear cell and
non-CCC (NCCC), due to different responses to sunitinib
[20]. Baseline data including those previously found to have
prognostic value [23,24] were collected retrospectively on
all patients using uniform database templates to ensure
consistent data collections and a SPSS databank was
created. Laboratory values were standardized according to
the local laboratory. The project was approved by local
ethical committees (No. 837/2014).
Parafﬁn-embedded tumor samples from all 64 patients
were retrieved from the Pathology Department of Barretos
Cancer Hospital, Barretos, Brazil. All 64 samples were from
the primary renal tumor (49 patients the material came from
a previous nephrectomy, and 15 patients the material came
from a biopsy from the primary tumor), and from these
patients we were able to retrieve 41 normal adjacent renal
tissue and 14 metastatic renal tissue. All tumor samples
were collected before treatment with sunitinib. The tumor
tissue were classiﬁed according to the latest criteria [25],
reviewed by experienced pathologists to select representa-
tive sections (tumor and normal) for TMA (tissue micro-
array) construction. The TMA blocks were done containing
2 representative areas of each primary cancer of RCC tissue,
metastatic tissue, and when available the normal counterpart
(1 mm diameter core).2.2. Immunohistochemistry analysis
Representative 4-µm thick sections of TMA were
subjected to immunohistochemistry according to the
streptavidin-biotin peroxidase complex system. Brieﬂy,
FFPE RCC tissue section were deparafﬁnised in oven at
80°C for 1 hour, following by antigen retriever by PT-
LINK–Dako, using commercial buffer Envision ﬂex target
retrieval solution high ph. x1, from Dako (pH ¼ 9). The
sections were then incubated with anti-Axl antibody
(dilution 1:50, Cat #AF154 R&D Systems, Minneapolis,
MN) at room temperature for 2 hours. As positive control,
we used normal breast tissue, which showed membranous
AXL staining of luminal ductal cells with variable
cytoplasmic staining, and cell-block of SNB-19 cell line,
known in previous studies of our group for high AXL
levels [21,26].
The score used was the sum of the percentage of
cytoplasm positive cells (negative, 0%–o1% positive cells;
1, 1%–10% positive cells; 2, 410%–50% positive cells;
3,4 50% positive cells) and the staining intensity (0,
negative; 1, weak; 2, moderate and 3, strong). Samples
with scores 0 to 2 were considered negative for AXL
expression and those with score 3 to 6 were considered
positive for AXL expression, as previously described for
receptor tyrosine kinase immunohistochemistry analysis
[27–29].
Table 1
Major clinical-pathological features of renal cell carcinomas tumors
Variable Clear cell Nonclear cell
Total patients
evaluated
n (%) Total patient
evaluated
n (%)
Age at diagnosiso57 y 51 27 52.9 13 5 38.5
Male 51 33 64.7 13 9 65.6
Time from diagnosis
to metastasis o1 y
51 37 72.5 13 11 84.6
Stage IV at diagnosis 51 27 52.9 13 8 61.5
Fuhrman grade
III and IV
36 20 55.6 7 4 57.1
Prior nephrectomy 51 43 84.3 13 10 76.9
Anemia 49 14 28.6 12 4 33.3
Neutrophilia 48 7 14.6 12 2 16.7
Plaquetosis 48 3 6.3 12 1 8.3
KPS ≤ 70 45 9 20.0 12 3 25.0
Time from diagnosis
to treatmento1 y
50 33 66.0 13 9 69.2
More than one site
of metastasis
51 28 54.9 13 10 76.9
Lung metastases present 51 33 64.7 13 8 61.5
Bone metastases present 51 16 31.4 13 5 38.5
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Cumulative survival probabilities were calculated using
the Kaplan-Meier method. Differences between survivals
were tested using the log-rank test. Our primary end point
was OS due to the retrospective analyses, which hamper a
proper progression-free survival. OS was deﬁned as the
time from metastatic diagnoses to death as a result of any
cause or was censored at the date of last follow-up.
Association between OS and prognostic factors were
assessed by using the long-rank test in univariable analysis.
Correlations between AXL expression and available
clinic-pathological data were performed using the Pearson's
chi-square test (χ2 test) or Fisher's exact test. The Cox
proportional hazard model was undertaken subsequently in
multivariable analyses by using a step-wise procedure with
a signiﬁcance level of 0.2 for entering and removing
variables.
The level of signiﬁcance in the statistical analysis were
indicated as Po 0.05. The statistical analysis was per-
formed using SPSS software for Windows, version 21.0.Liver metastases
present
51 10 19.6 13 3 23.1
Brain metastases
present
51 1 2.0 13 1 7.7
Sarcomatoid features 51 4 7.8 13 2 15.4
TKI as ﬁrst systemic
treatment
49 35 71.4 13 11 84.6
KPS ¼ Karnofsky performance status.3. Results
3.1. Patient clinical-pathological features
Overall, 64 patients were included in this analysis that
were divided in 2 major subgroups: 51 (79.6%) CCC cases;
and 13 (20.4%) NCCC cases (Table 1). Among the CCC
subgroup, 4 (6.3%) cases were CCC with sarcomatoid
features, and within the NCCC group, 9 cases (14%) were
papillary RCC and 4 (6.3%) were RCC, unclassiﬁed, where
2 cases had pure sarcomatoid features. Forty-two (65.6%)
were male and 22 (34.4%) were female with a median age
of 57-years old (range: 30–81). The clinical parameters
available for the two groups showed similar proﬁle
(Table 1). The median OS for the entire cohort of 64
patients was 25.6 months (95% CI: 11.6–39.7 mo, Fig. 1A).
The mean follow up was 18.5 months. The CCC cohort,
which compromised 51 patients, the OS was 26.3 months
(95% CI: 6.0–46.5 mo) and the NCCC cohort, which
compromised 13 patients, the OS was 10.3 months (95%
CI: 5.1–15 mo, Fig. 1B).
In the ﬁrst line therapy 46 (72%) patients received a TKI,
and sunitinib was the drug of choice in the 45 patients,
followed by 16 (25%) patients that received interferon alfa.
One patient received chemotherapy as ﬁrst line and one
patient was not treated with any systemic therapy. Of the 45
patients that received sunitinib as ﬁrst line, 26 (58%) had
progressed while using sunitinib, 11 (24%) had partial
response or stable disease, and 8 (18%) the data were
missing.
Seventeen patients did not receive sunitinib as ﬁrst line,
but it was giving at point of treatment. Thirteen patients
received in the second line, three patients received in thethird line and one patient in the fourth line. Of those
patients 8 (47%) had progressed disease and 9 (53%) had
partial response or stable disease while in use of sunitinib.3.2. AXL expression in patients with RCC
The immunohistochemistry analysis of the 64 cases
showed a wide variety of expression patterns, from negative
to highly positive membranous or cytoplasmatic immunos-
taining (Fig. 2). Negative immunostaining (scores 0–2þ)
(Fig. 2A) was present in 34 (53.2%) patients and positive
immunostaining (scores: 3þ to 6þ) (Fig. 2B and C) was
present in 30 (46.8%) of 64 cases. Endothelial cells were
highly positive and it was used as internal control (Fig. 2).
When analyzed all AXL scores cases separately from 0
through 6þ, it was seen that 26 (41%) cases had score 0, 8
(13%) had score 2þ, 4 (6%) had score 3þ, 15 (23%) had
score 4þ, 4(6%) had score 5þ and 7 (11%) had score 6þ
(Fig. 3).
We also evaluated the AXL positivity in the normal renal
tissue of 41 patients and in the metastasis tissue of 14
patients. We could observe a rising in AXL positivity from
normal renal tissue to tumor renal tissue and from a tumor
renal tissue to a metastatic renal tissue, but with no
statistical signiﬁcance (Fig. 4A and B).
Fig. 1. (A) Overall survival according to initial metastasis diagnosis. (B) Overall survival according to initial metastasis diagnosis and subgroups RCC (clear
cell and nonclear cell).
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distinct histological subtypes. The clear cell subtype depicted a
43.1% (22/51) of AXL positivity, whereas the nonclear cell
subtype showed a 61.5% (8/13) of positive AXL expression.
3.3. Association between AXL expression and clinical-
pathological features
The univariate analysis between the AXL expression and
clinical-pathological features for both histological subtypes
combined, demonstrated that AXL positivity was associated
with poor prognostic feature, like thrombocytosis, time
from diagnostic to treatment less than a year, presence of
bone metastasis, presence of brain metastasis and sarcoma-
toid histology, but none were statically signiﬁcant
besides progression while in sunitinib therapy (Table 2).
In multivariate analysis, none of the variables had statically
signiﬁcance correlation with AXL positivity.Fig. 2. Representative pictures of IHC analysis of AXL expression in clear cell R
endothelial cells. (A) Negative immunostaining. (B) Positive immunostaining scoWhen analyze only the patients with CCC, in univariate
analysis we also demonstrated that AXL positivity was
associated with poor prognostic features, like thrombocy-
tosis, time from diagnoses to treatment less than a year,
presence of bone metastasis, presence of brain metastasis
and sarcomatoid histology, but only older patients and
progression while in sunitinib therapy was statistical sig-
niﬁcant (Table 2). In multivariate analysis older patients
(HR ¼ 4.75; 95% CI: 1.2–17.7; P ¼ 0.020) and presence
of bone metastasis (HR ¼ 4.78; 95% CI: 1.17–19.4;
P¼ 0.029) were signiﬁcantly associated with AXL positivity.
The overall response while using sunitinib of the entire
cohort of 64 patients, 35 (54.7%) patients had progression,
19 (29.7%) had stable or response disease, and 10 (15.6%)
patients we were not able to access a response rate. In the
univariate analysis, between all patients that used sunitinib
and had AXL positivity, 21 (77.8%) patients had disease
progression and 6 (22.2%) patients had response or stableCC tissue (×100 scale and in right bottom ×400 scale). Positive marks in
re 4þ. (C) Positive immunostaining score 6þ.
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Fig. 3. AXL immunohistochemistry analysis of the 64 cases from 0
through 6þ.
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(51.9%) patients had disease progression and 13 (48.1%)
patients had response or stable disease (P ¼ 0.046)
(Fig. 5A). Among only those with clear cell subtype,
patients with AXL positivity, 16 (80%) patients had disease
progression and 4 (20%) patients had response or stable
disease while using sunitinib, while between patients with
AXL negativity, 10 (43.5%) patients had disease progres-
sion and 13 (56.5%) patients had response or stable disease
(P ¼ 0.027) (Fig. 5B).
3.4. AXL expression predicts poor prognosis in patients
with RCC
We further evaluated the association of AXL expression
with patient outcome. We found that patients with positive
AXL expression had a median OS of 41.2 months (95% CI:
10.1–72 mo), compared to 19 months (95% CI: 7.0–32 mo)
of patients AXL negative, however, not reaching statistical
signiﬁcance (P ¼ 0.14) (Fig. 6A). The multivariateFig. 4. AXL expression in different types of tissue. (A) AXL expression in 41 patie
in 14 patients that had renal tumor tissue and metastatic tissue.analysis showed that AXL expression was a poor prognos-
tic factor in patients with mRCC (HR ¼ 2.007; CI: 1.006–
4.006; P ¼ 0.048). In addition of the positivity for AXL,
other prognostic factors were absence of nephrectomy,
more than 1 site of metastasis and bone metastasis
(Table 3). Interestingly, when we stratiﬁed the positive
AXL expression (3þ thought 6þ) there were no difference
in OS between groups (data not shown).
When we stratiﬁed by histological subtype, the CCC
AXL negative cases (n ¼ 22), exhibited an OS of 43.3
months (95% CI: 18.1–68 mo), whereas in the AXL
positive cases (n ¼ 29) was of 13.4 months (95% CI:
4.0–22 mo), also not reaching a signiﬁcance (P ¼ 0.055)
(Fig. 6B). In multivariate analysis, AXL positivity in CCC
was associated with poor prognostic along with absence of
nephrectomy, Karnofsky performance status less than 70,
more than 1 site of metastasis and presence of liver
metastasis (Table 4).4. Discussion
Despite the advanced systemic treatment in mRCC in the
past 10 years and the multiples drugs available [5,12],
treatment decision is based in medical expertise rather than
in objective predictive biomarkers [30]. With the in vitro
evidences that tyrosine kinase AXL expression can be a
predictive biomarker to sunitinib [21], our group inves-
tigated in the present study whether AXL overexpression in
tumor renal tissue is associated with response rate in mRCC
patients treated with sunitinib.
We analyzed 64 patients with mRCC treated with
sunitinib. Demographic parameters and OS were similar with
previous studies [23,31]. We could not correlate increased
expression AXL with tumor response to sunitinib. However,nts that had normal renal tissue and renal tumor tissue. (B) AXL expression
Table 2
Univariate analysis between AXL expression and clinical-pathological features
Variable All subtype Clear cell subtype
Positive (n) P value (%) Positive (n) P value (%)
Sex Male 22 52 0.223 16 48 0.29
Female 8 3 6 33
Age at diagnosis o57 y 12 38 0.133 8 30 0.039
≥57 y 18 56 14 58
Hemoglobin concentration, g/dl 411 5 29 0.10 3 23 0.093
≤11 23 52 18 50
Corrected calcium concentration ULN 10 53 0.71 7 50 1a
4ULN 6 46 5 50
Neutrophil count, /mm3 ≤7,500 25 49 0.38 18 44 1
47,500 3 33 3 43
Platelet count ≤450.000 26 46 1a 19 42 0.57a
4450.000 2 50 2 67
Karnofsky performance status 470 25 56 0.06 18 50 0.37
≤70 2 25 3 33
Time from diagnosis to treatment 41 y 8 38 0.28 5 29 0.13
≤1 y 22 52 17 74
Number of metastatic sites 1 site 11 42 0.545 9 39 0.60
41 site 19 50 13 46
Lung metastasis Absent 13 56 0.3 9 50 0.465
Present 17 41 13 39.4
Bone metastasis Absent 19 44 0.6 12 34 0.059
Present 11 52 10 63
Liver metastasis Absent 24 47 0.95 18 44 0.823
Present 6 46 4 40
Brain metastasis Absent 28 45 0.21a 21 42 0.43a
Present 2 100 1 100
Histological type Clear cell 22 43 0.235
Nonclear cell 8 62
Sarcomatoid features Absent 26 45 0.40 19 40 0.30
Present 4 67 3 75
Response to sunitinib Stable/partial response 6 32 0.046 4 24 0.015
Progression 21 60 19 40
aFisher's exact test.
L.E. Zucca et al. / Urologic Oncology: Seminars and Original Investigations 36 (2018) 11.e13–11.e2111.e18we observed that AXL positivity in kidney cancer tissue is
associated with shorter survival and a lack of response to the
treatment.Fig. 5. Overall response to sunitinib according to AXL expressAXL overexpression in tumor tissue has been associated
with poor prognoses in a variety of cancers, probably
because its involvement in various aspects of cellularion. (A) Entire cohort. (B) Patients with clear cell RCC.
Fig. 6. (A) Overall survival of the entire cohort according to initial metastasis diagnosis and AXL expression. (B) Overall survival only the subtype clear cell
RCC according to initial metastasis diagnosis and AXL expression.
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of cancer [16]. Recent reports showed that high tumor AXL
was an independent prognostic factor in patients with RCC
[32,33]. Gustafsson et al. [32] in 2009, reported the tumor
Axl mRNA was as an independent prognostic factor in
cancer-speciﬁc survival, and Rankin et al. [33] in 2015
analyzed AXL expression in human RCC tissue within The
Cancer Genome Atlas (TCGA) and samples with strong
AXL expression was associated patients with reduced
survival compared with patients whose samples had
weak AXL expression. Our report, represents the ﬁrst
association of AXL positivity by immunohistochemistry
with reduced survival in patients with mRCC treated with
sunitinib.
AXL has been suggested to promote both intrinsic and
acquired resistance to different treatments, from chemo-
therapy to molecular targets [15]. In RCC xenograft models
upregulation of AXL and MET showed resistance to long-
term sunitinib therapy, as well as resensitisation to sunitinib
after AXL and MET inhibition via treatment with the TKI
cabozantinib [34]. Cabozantinib has been demonstrated
efﬁcacy in 2 trials in mRCC [35,36]. A large phase III trialTable 3
Multivariable analysis—association of overall survival with prognostic risk
factors in all subtypes patients
Parameter All subtypes
Hazard ratio (95% CI) P value
AXL positivity 2.007 (1.006–4.006) 0.048
Absence of nephrectomy 4.848 (1.945–12.081) 0.001
Presence of bone metastases 2.952 (1.514–5756) 0.001
More than 2 sites of metastases 2.989 (1.506–5.929) 0.002demonstrated that cabozantinib increased OS, delayed
disease progression, and improved the objective response
compared with everolimus after failing one or more anti-
VEGF [35]. Recently cabozantinib was compared to
sunitinib in ﬁrst-line therapy in intermediated and poor risk
IMDC (International Metastatic Renal Cell Carcinoma
Database Consortium) group patients and was observed
that cabozantinib had beneﬁt in progression-free survival
and overall response rate over sunitinib [36]. None of these
2 trials used a biomarker for predictive response to therapy.
Despite of a variety promising new drugs emerging in the
scenario of ﬁrst-line therapy of mRCC, sunitinib might still
have its place in some patients, namely in those cases with
lack of AXL expression.
Our sample is representative of mRCC treated with
sunitinib. However, the results from CCC setting have
limited inference due to small exploratory sample
(n ¼ 51). Additionally, the signiﬁcance of survival
differences in CCC according to AXL staining is
tangential. Unfortunately, we were unable to deﬁne risk
criteria according Motzer et al. [24] and Heng et al. [23]Table 4
Multivariable analysis—association of overall survival with prognostic risk
factors in patients with clear cell carcinoma
Parameter Clear cell carcinoma
Hazard ratio (95% CI) P value
AXL positivity 5.350 (2.062–13.885) 0.001
Absence of nephrectomy 8.383 (2.774–25.332) 0.000
More than two sites of metastases 3.895 (1.266–13.982) 0.002
Presence of liver metastases 4.208 (1.266–13.982) 0.019
KPSo 80% 2.603 (1.040–6.515) 0.041
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further studies are warranted to extend and validate the
present ﬁndings.5. Conclusion
In the present study we reported that AXL was a
prognostic biomarker in patients with mRCC treated with
sunitinib. Interesting, AXL constitute also a target of the
new drug cabozantinib, which demonstrated efﬁcacy in the
treatment in mRCC patients. Further studies are needed to
demonstrate that cabozantinib is a target against patients
with increased AXL expression.Acknowledgments
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